.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC21_Treprostinil.Treprostinil_1 .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC21_Treprostinil.Treprostinil_1| name: | Treprostinil_1 |
| ATC code: | B01AC21_1 | route: | oral |
| n-compartments | 2 |
Treprostinil is a stable, synthetic analog of prostacyclin (PGI2) used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. It acts as a vasodilator of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. It is approved for use in several countries and can be administered intravenously, subcutaneously, orally, or by inhalation.
Pharmacokinetic parameters in healthy adults after oral administration of treprostinil extended-release tablets.
de Lartigue, J (2014). Oral treprostinil for the treatment of pulmonary arterial hypertension. Drugs of today (Barcelona, Spain : 1998) 50(8) 557–565. DOI:10.1358/dot.2014.50.8.2207312 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25187906
Wu, X, et al., & Venkataramanan, R (2022). Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment. British journal of clinical pharmacology 88(2) 587–599. DOI:10.1111/bcp.14966 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34190364
Galiè, N, et al., & Branzi, A (2003). Prostanoids for pulmonary arterial hypertension. American journal of respiratory medicine : drugs, devices, and other interventions 2(2) 123–137. DOI:10.1007/BF03256644 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14720012